Natera, Inc. (NTRA)
| Market Cap | 41.68B +47.9% |
| Revenue (ttm) | 2.91B +37.4% |
| Net Income | -164.71M |
| EPS | -1.16 |
| Shares Out | 145.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,246,958 |
| Open | 294.10 |
| Previous Close | 288.48 |
| Day's Range | 277.23 - 297.00 |
| 52-Week Range | 181.00 - 437.41 |
| Beta | 1.52 |
| Analysts | Strong Buy |
| Price Target | 409.62 (+42.49%) |
| Earnings Date | Nov 5, 2026 |
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizo... [Read more]
Financial Performance
In 2025, Natera's revenue was $2.31 billion, an increase of 35.90% compared to the previous year's $1.70 billion. Losses were -$208.16 million, 9.31% more than in 2024.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $409.62, which is an increase of 42.49% from the latest price.
News
HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named the Best in Class winner in the Cancer, Scr...
Natera registers to sell 68,023 shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 68,023 shares of common stock. The company is not selling any…
Natera Transcript: 8th Annual Wolfe Research Healthcare Conference
Solomon’s immediate CEO transition is framed as continuity, while a $6B 2029 revenue target rests partly on Signatera growth and reimbursement expansion. Management estimates a $20B-$40B Signatera TAM and sees early cancer detection as a potential further expansion around 2030-2031.
Natera announces clinical collaboration with Incyte
Natera (NTRA) announced that it has entered into a clinical collaboration agreement with Incyte (INCY) for a new phase II study in colorectal cancer, CRC. The trial will evaluate INCA33890,…
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with In...
Natera Transcript: UBS Global Healthcare Conference
The CEO handoff was presented as a continuity move backed by a tenured team. The 2029 $6B revenue target relies on continued Signatera growth, while colorectal screening and Japan provide longer-term expansion paths.
Natera price target lowered to $405 from $475 at Roth Capital
Roth Capital analyst Max Masucci lowered the firm’s price target on Natera (NTRA) to $405 from $475 and keeps a Buy rating on the shares. The surprising CEO transition has…
Natera price target lowered to $403 from $458 at Baird
Baird lowered the firm’s price target on Natera (NTRA) to $403 from $458 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results. Published…
Natera price target lowered to $405 from $460 at JPMorgan
JPMorgan lowered the firm’s price target on Natera (NTRA) to $405 from $460 and keeps an Overweight rating on the shares. The firm says heightened expectations into the Q3 report…
Natera reports Q3 EPS (42c), consensus (28c)
Reports Q3 revenue $794M, consensus $707.5M.
Natera raises FY26 revenue $3.005B-$3.035B, consensus $2.91B
Previous view $2.85B-$2.91B. Natera (NTRA) anticipates 2026 total revenue of $3.005 billion to $3.035 billion; gross margin to be approximately 64% to 66%; selling, general and administrative costs to...
Natera Earnings Call Transcript: Q3 2026
Q3 revenue rose 34% YoY to $794M, while clinical MRD units grew 56%. FY2026 revenue guidance increased to $3.005B-$3.035B, alongside a $6B revenue target for 2029.
Natera Earnings release: Q3 2026
Natera released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Natera Slides: Q3 2026
Natera has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Natera Quarterly report: Q3 2026
Natera has published its Q3 2026 quarterly earnings report on November 5, 2026.
Natera Announces Leadership Transition
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Solomon Moshkevich has been appointed Chief Executive Officer...
Natera Reports Third Quarter 2026 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 202...
Natera to present new Signatera data at SITC Annual Meeting
Natera (NTRA) announced it will present important new Signatera data at the Society for Immunotherapy of Cancer, SITC, Annual Meeting, taking place November 4-8 in Phoenix, Arizona. A real-world analy...
Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present important new Signatera data at the Society for Im...
Natera announces three peer-reviewed publications in npj Precision Oncology
Natera (NTRA) announced three peer-reviewed publications in npj Precision Oncology, JAMA Otolaryngology, and Advances in Radiation Oncology, highlighting the performance of its Signatera test in head ...
Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced three peer-reviewed publications in npj Precision Oncology, JAMA O...
Natera announces its Signatera MRD test received Medicare coverage
Natera (NTRA) announced that its Signatera molecular residual disease, MRD, test has received Medicare coverage through the Centers for Medicare & Medicaid Services’, CMS, Molecular Diagnostics Servic...
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has recei...
Natera to Report its Third Quarter Results on November 5, 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September...
Natera highlights Signatera Genome Assay at ESMO Congress
Natera (NTRA) provided a summary of key findings from the European Society for Medical Oncology Congress 2026. Following the presentation of several late-breaking datasets over the weekend, Natera’s t...